GYRE

In the past six months (March-September 2026), Gyre Therapeutics experienced several stock-impacting events. The acquisition of Cullgen Inc. in May 2026, an all-stock transaction valued at approximately $300 million, expanded Gyre's pipeline into targeted protein degradation therapies. China's NMPA accepted the New Drug Application (NDA) for F351 for CHB-induced liver fibrosis treatment in May 2026, following priority review status granted in March 2026. For earnings, Q1 2026 reported $22.5 million in revenue and a GAAP basic EPS of ($0.10), while Q2 2026 reported $29.1 million in revenue (exceeding expectations) but a GAAP basic EPS of ($0.12) (missing estimates), with a 2% revenue decrease year-over-year primarily due to lower collaboration revenue. In July 2026, three new members were appointed to the Board of Directors. As of September 2026, the stock increased by 6.85% over the last six months and 6.9% year-to-date, trading at $7.55 with an average analyst target price of $18.67.